KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Current Taxes (2016 - 2025)

Abbott Laboratories' Current Taxes history spans 17 years, with the latest figure at $569.0 million for Q4 2025.

  • For Q4 2025, Current Taxes fell 4.21% year-over-year to $569.0 million; the TTM value through Dec 2025 reached $569.0 million, down 4.21%, while the annual FY2025 figure was $569.0 million, 4.21% down from the prior year.
  • Current Taxes for Q4 2025 was $569.0 million at Abbott Laboratories, up from $469.0 million in the prior quarter.
  • Across five years, Current Taxes topped out at $713.0 million in Q3 2024 and bottomed at $242.0 million in Q2 2021.
  • The 5-year median for Current Taxes is $379.0 million (2021), against an average of $421.1 million.
  • The largest annual shift saw Current Taxes surged 214.53% in 2021 before it tumbled 35.11% in 2025.
  • A 5-year view of Current Taxes shows it stood at $306.0 million in 2021, then rose by 12.09% to $343.0 million in 2022, then soared by 43.44% to $492.0 million in 2023, then increased by 20.73% to $594.0 million in 2024, then dropped by 4.21% to $569.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Current Taxes are $569.0 million (Q4 2025), $469.0 million (Q3 2025), and $390.0 million (Q2 2025).